Faculty: Biography
 |
Robert D. Arnold, Ph.D. Assistant Professor Pharmaceutical and Biomedical Sciences
|
| Biosketch | |||
|---|---|---|---|
| B.S. Biochemistry | State Univ. of New York | Plattsburgh, NY | 1994 |
| Ph.D. Pharmaceutical Sciences | University at Buffalo | Amherst, NY | 2004 |
- Post-doctoral Experience
- Postdoctoral Associate, University at Buffalo & Roswell Park Cancer Institute, Buffalo, NY, 2004-2005
- Honors and Awards
- Georgia Cancer Coalition (GCC) Distinguished Cancer Scholar, 2007
Chair, American Association of Pharmaceutical Scientists (AAPS) - Student Postdoc Outreach & Development Committee, 2005-present
Fellow - American Foundation for Pharmaceutical Education, 1999
- Research Interests
- Research and development of chemotherapeutic agents for the treatment of cancer. A broad goal is to utilize a systems approach integrating in vitro data on the effect of drug and tumor microenvironment on cell growth with the development of optimal nanoparticulate drug carriers and dosing schedules. In pursuing this research, pharmacokinetic (PK) and pharmacodynamic (PD) principles are utilized as tools for the selection of novel therapeutic agents, design of rational drug delivery strategies to improve therapy, and elucidation of mechanisms underlying drug action. Passive and actively targeted drug delivery strategies, in particular lipid based nanoparticulate drug carriers (e.g., small, long-circulating liposomes), are engineered with maximal drug capacity and various release profiles to achieve optimal exposure at the target site, while limiting systemic toxicity by minimizing delivery to reactive non-target tissues. The composition, drug-delivery system interaction, and dosing regime are modulated to exploit differences in tumor microenvironment (e.g., pH, oxygenation, enzymatic expression) to trigger drug release and improve overall treatment efficacy. The primary objective is to develop a multi-drug therapeutic approach, combining vascular targeting and conventional oncolytic agents to induce immediate tumor regression and/or facilitate long-term tumor dormancy.
- Representative Publications
- Carl, S.M., Knipp, G.T., Hussain, A., Morris, K.R., Lindley, D.J., and Arnold, R.D., Biotechnology Product Development. In: Gad, SC, editor. Pharmaceutical Manufacturing Handbook: Production and Processes, New Jersey: John Wiley and Sons; 2008
Bulitta, J.B., Zhao, P., Arnold, R.D., Kessler, D.R., Daifuku, R., Pratt. J., Luciano, G., Hanauske, A.R., Gelderblom, H., Awada, A., and Jusko, W.J., (2009) Mechanistic Population Pharmacokinetics of Total and Unbound Paclitaxel for a New Nanodroplet Formulation vs. Taxol in Cancer Patients, Cancer Chemotherapy and Pharmacology, 63:1035-1048 (Epub 8/08)
Bulitta, J.B., Zhao, P., Arnold, R.D., Kessler, D.R., Daifuku, R., Pratt. J., Luciano, G., Hanauske, A.R., Gelderblom, H., Awada, A., and Jusko, W.J., (2009) Multiple-Pool Lifespan Models for Neutropenia to Characterize the Population Pharmacodynamics of Unbound Paclitaxel from Two Formulations in Cancer Patients, Cancer Chemotherapy and Pharmacology, 63:1049-1063 (Epub 8/08)
Kim, Y., Lee, H., Jung, J., Rivner, J., Lutz, R., Arnold, R.D., Garti, N., Wicker, L., Valencia orange pectinmethylesterases, charge modification, and applications to food technology and drug delivery, In: Pectins and Pectinases, H.A. Schols, R.G.F. Visser and A.G.J. Voragen (eds), Wageningen Academic Publishers, Wageningen, 231-243. ISBN: 978-90-8686-108-8
Zhang, S., Sagawa, K., Arnold, R.D., Tseng, E., Xiaougdong, W., Morris, M.E., Interactions between the Flavonoid Biochanin A and P-glycoprotein Substrates in Rats: In Vitro and In Vivo, 2010 Journal of Pharmaceutical Sciences, 99(1):430-41.